AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17941026
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of liposomal amphotericin B (AmB) at 3 mg/kg daily and caspofungin at standard dose
Trial: 17941026
Drug: High-dose monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose monotherapy with liposomal amphotericin B at 10 mg/kg daily
Trial: 11564124
Drug: Levetiracetam (1,000-3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (1,000-3,000 mg/day)
Trial: 9636808
Drug: Sublingual-swallow immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual-swallow immunotherapy (SLIT) with standardized grass-pollen extract
Trial: 7868848
Drug: Oral tacrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tacrine (25 and 50 mg b.i.d.)
Trial: 7868848
Drug: Rectal tacrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal tacrine (12.5 and 25 mg b.i.d.)
Trial: 7868848
Drug: Rectal tacrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal tacrine
Trial: 7868848
Drug: Oral tacrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tacrine
Trial: 26507186
Drug: Sufficient vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufficient vitamin D levels (>30 ng/ml)
Trial: 26507186
Drug: Insufficient vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insufficient vitamin D (<30 ng/ml)
Trial: 26507186
Drug: Deficient vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deficient vitamin D (<20 ng/ml)
Trial: 26507186
Drug: Each 1
RxNorm normalized name: ClindaReach 1% Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 1 ng/ml increase in 25(OH)D
Trial: 20849470
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg controlled-release levodopa/carbidopa
Trial: 20849470
Drug: Off-state (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Off-state (no treatment)
Trial: 16467101
Drug: Dendritic cell-MFP
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell-MFP therapy
Trial: 9359722
Drug: Clarithromycin plus
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin plus clofazimine plus ethambutol (three-drug arm)
Trial: 9359722
Drug: Clarithromycin plus
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin plus clofazimine (two-drug arm)
Trial: 7994648
Drug: Oral Vit
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Vit B2 5mg three times a day during phototherapy
Trial: 2657838
Drug: Buspirone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (15 mg/day, flexible to 30 mg/day, mean daily dose 20.5 mg)
Trial: 820622
Drug: TRH injection
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TRH injection
Trial: 31438912
Drug: Housing First
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Housing First with Assertive Community Treatment (HF with ACT)
Trial: 22043463
Drug: Open flap
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open flap implant placement
Trial: 7857222
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant growth hormone (rGH) 0.2 iu/kg daily for 7 days
Trial: 7857222
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) injection daily for 7 days
Trial: 2034244
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (cisplatin and fluorouracil) followed by radiation therapy
Trial: 1469466
Drug: Surgery followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery followed by radiation therapy
Trial: 16435478
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for duodenal ulcer
Trial: 30569748
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg inhaled terbutaline
Trial: 30569748
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg inhaled terbutaline
Trial: 2714503
Drug: Lamicel with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamicel with intravenous oxytocin
Trial: 2714503
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with intravenous oxytocin
Trial: 21863638
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy de novo of adefovir dipivoxil (ADV) 10 mg per day and lamivudine (LMV) 100 mg per day
Trial: 21863638
Drug: Monotherapy of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy of lamivudine (LMV) 100 mg per day
Trial: 21863638
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy de novo of adefovir dipivoxil (ADV) and lamivudine (LMV)
Trial: 21863638
Drug: Monotherapy of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy of lamivudine (LMV)
Trial: 19255394
Drug: 4-hour adolescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-hour adolescent medicine workshop using standardized patients (n = 95)
Trial: 15054026
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment (attendance of a course involving theoretical and practical sessions)
Trial: 15054026
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (mailed information about BSE)
Trial: 11388817
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (conjugated estrogens plus medroxyprogesterone)
Trial: 8306923
Drug: Bromazepam 12
RxNorm normalized name: bromazepam 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam 12 mg/d
Trial: 8306923
Drug: Prazeapam 40
RxNorm normalized name: prazepam
DrugBank: Prazepam (DB01588)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prazeapam 40 mg/d
Trial: 30584287
Drug: Extracorporeal magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal magnetic innervation (ExMI) therapy, 15 minutes, three times a week for 4 weeks
Trial: 30584287
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (ExMI therapy) vs Control group (no intervention)
Trial: 26448141
Drug: Artefenomel 200
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 200 mg
Trial: 26448141
Drug: Artefenomel 400
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 400 mg
Trial: 26448141
Drug: Artefenomel 800
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 800 mg
Trial: 26448141
Drug: Artefenomel 1200
RxNorm normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel 1200 mg
Trial: 26448141
Drug: Artefenomel (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel (all doses)
Trial: 22344065
Drug: Stretching of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretching of the antagonist musculature
Trial: 9740347
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training at 30% of maximum inspiratory mouth pressure for 30 min daily
Trial: 8092115
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of metoclopramide (regimen A)
Trial: 8092115
Drug: Intermittent short
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent short infusion of metoclopramide (regimen B)
Trial: 6214996
Drug: Moxalactam (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam (500 mg every 12 h)
Trial: 6214996
Drug: Cefazolin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1 g every 12 h)
Trial: 27139726
Drug: Norepinephrine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 5 µg ml-1
Trial: 27139726
Drug: Phenylephrine 100
RxNorm normalized name: phenylephrine 100 mcg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 100 µg ml-1
Trial: 24622121
Drug: AAV1/SERCA2a gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV1/SERCA2a gene therapy
Trial: 22935527
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy in non-CKD (n=4,747)
Trial: 22935527
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy in mild CKD (n=2,135)
Trial: 22935527
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy in severe CKD (n=229)
Trial: 22935527
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy in HD (n=117)
Trial: 19663622
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment control group (n = 68)
Trial: 17464561
Drug: Esomeprazole, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole, 20 mg bid with amoxicillin, 1000 mg bid, and clarithromycin, 500 mg bid for 1 week, followed by placebo for 3 weeks
Trial: 17464561
Drug: Omeprazole, 20
RxNorm normalized name: Omeprazole, 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 20 mg bid with amoxicillin, 1000 mg bid, and clarithromycin, 500 mg bid for 1 week, followed by omeprazole, 20 mg od for 3 weeks
Trial: 15247714
Drug: PNB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNB plus rectal lidocaine gel
Trial: 12566834
Drug: Intracystic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracystic chemotherapy with bleomycin (group A)
Trial: 30488513
Drug: Coronary artery
RxNorm normalized name: Drug-coated coronary artery stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronary artery bypass grafting surgery plus medical therapy
Trial: 25931316
Drug: Pidotimod 400
RxNorm normalized name: pidotimod 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidotimod 400 mg per os twice daily for the last 10 days of each month from October 2013 to April 2014
Trial: 19564809
Drug: Topical and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical and intraurethral lidocaine
Trial: 19564809
Drug: Topical lubricant
RxNorm normalized name: emollient base TOPICAL LUBRICANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lubricant control
Trial: 15015186
Drug: EVAR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVAR with best medical treatment
Trial: 11163386
Drug: Single-unit all-porcelain
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-unit all-porcelain crowns (SUAPC) preparation with acid etching
Trial: 7828353
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone therapy (0.2 IU/kg/week for 6 months)
Trial: 7828353
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone therapy (12 months)
Trial: 7828353
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro glucocorticoid sensitivity during GH therapy
Trial: 7828353
Drug: Placebo arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm during open phase of GH therapy
Trial: 3277478
Drug: Morphine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.25 mg (group I, n = 11)
Trial: 3277478
Drug: Morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.1 mg (group II, n = 10)
Trial: 22122992
Drug: Memantine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine treatment
Trial: 12571662
Drug: Psyllium-enriched pasta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium-enriched pasta (1.7 g psyllium)
Trial: 12571662
Drug: Pasta with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasta with 30 g sunflower oil and 3 g sodium propionate
Trial: 30662380
Drug: Conventional one-on-one
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional one-on-one occupational therapy interventions
Trial: 20122815
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition supplemented with glutamine 0.18 g kg(‐1) d(‐1) for 20 d
Trial: 17768157
Drug: Indometacin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (0.2 mg/kg)
Trial: 12701260
Drug: Subarachnoid anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid anesthesia with 5 mg of bupivacaine and 15 micrograms of fentanyl (Group F)
Trial: 12701260
Drug: Subarachnoid anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid anesthesia with 7.5 mg bupivacaine (Group B)
Trial: 8914088
Drug: Sublingual apomorphine
RxNorm normalized name: apomorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual apomorphine (10 mg)
Trial: 8914088
Drug: Sublingual apomorphine
RxNorm normalized name: apomorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual apomorphine with Vitamin C (250 mg)
Trial: 1860146
Drug: Ivermectin 100
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 100 micrograms/kg given at 2-week intervals for 6 doses
Trial: 26450146
Drug: Hydrocortisone (H)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (H) 10 mg p.o. + placebo i.v.
Trial: 26450146
Drug: Fludrocortisone (FC)
DrugBank: Fludrocortisone (DB00687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone (FC) 0.1 mg p.o. + placebo i.v.
Trial: 26450146
Drug: Fludrocortisone (FC)
DrugBank: Fludrocortisone (DB00687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone (FC) 0.1 mg p.o. and Hydrocortisone (H) 10 mg p.o. + placebo i.v.
Trial: 18271229
Drug: Blood-letting puncture
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood-letting puncture at 12 Jing-well points of the hand combined with fuming and washing with herbal lotion
Trial: 18271229
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of diuretic
Trial: 7585844
Drug: Risperidone (9.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (9.4 mg/d for 1 year)
Trial: 7585844
Drug: Risperidone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (2 years treatment)
Trial: 2262587
Drug: Chlorhexidine acetate
RxNorm normalized name: Chlorhexidine Acetate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine acetate (CHX) gum, 5 mg per piece, chewed 2 pieces 2 times daily for 10 min
Trial: 2262587
Drug: Chlorhexidine acetate
RxNorm normalized name: Chlorhexidine Acetate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine acetate (CHX) gum, 4 mg per piece, chewed 2 pieces 2 times daily for 6 days
Trial: 2262587
Drug: Chlorhexidine acetate
RxNorm normalized name: Chlorhexidine Acetate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine acetate (CHX) gum, 3 mg per piece, chewed 2 pieces 2 times daily for 6 days
Trial: 2262587
Drug: Gum base
RxNorm normalized name: Gum base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum base without CHX or sweetening agent
Trial: 31858394
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg) 5 min before induction, followed by infusion (2 mg/kg/h) until the end of surgery
Trial: 31858394
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution (placebo) and infusion of 0.9% saline solution during surgery
Trial: 30996008
Drug: Hypofractionated stereotactic
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated stereotactic radiotherapy (HFSRT) concurrent with temozolomide (TMZ) at a dosage of 75 mg/m2 per day for at least 20 days
Trial: 21658782
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of d,l-fenfluramine (FEN)
Trial: 2526239
Drug: Cyclo provera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclo provera (Depo‐medroxy Progesterone Acetate 25 mg and Estradiol Cypionate 5 mg)
Trial: 2526239
Drug: HRP-102 (Norethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRP-102 (Norethisterone enanthate 50 mg and Estradiol Valerate 5 mg)
Trial: 23607542
Drug: Oral vestibular
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vestibular cleansing capability assessment (measuring rice remaining in the oral vestibule)
Trial: 19153091
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aspirin daily starting on the first day of gonadotrophin stimulation
Trial: 9778268
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral steroids
Trial: 9778268
Drug: Interferon beta-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1b (IFNbeta-1b) therapy
Trial: 26228433
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with gemcitabine and cisplatin for 24 weeks
Trial: 28388820
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (methotrexate, sulfasalazine, and hydroxychloroquine)
Trial: 23755969
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (after switching therapies)
Trial: 15013587
Drug: Hyperfractionated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiotherapy (RT) with concurrent carboplatin/vindesine followed by surgery (arm A)
Trial: 9840854
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tramadol
Trial: 9840854
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg metoclopramide
Trial: 9840854
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg lidocaine
Trial: 9840854
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL normal saline
Trial: 8077826
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous injection of local anaesthetic beneath the cuff
Trial: 2683281
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase (SK) - intravenous infusion of 1.5 million International Units during one hour
Trial: 2683281
Drug: Acetyl salicylic
RxNorm normalized name: Acetyl salicylic acid specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl salicylic acid (ASA) - 160 mg daily for 30 days
Trial: 2683281
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SK and ASA
Trial: 2683281
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment only